Clinical Trials
14 trialsNCT05417594 2026-05-05
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT01009788 2025-03-14
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT03190967 2023-10-11
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01506609 2021-10-25
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
AbbVie
Phase 2 Completed
NCT00617539 2018-04-20
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Phase 2 Completed
NCT00526617 2017-11-21
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
AbbVie
Phase 1 Completed
NCT00638963 2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00831545 2017-05-09
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00005054 2013-09-20
Temozolomide in Treating Women With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00614978 2012-09-19
LAPTEM
Jules Bordet Institute
Phase 1 Completed
NCT00629187 2012-04-27
CN-306
Tufts Medical Center
Phase 1 Terminated
NCT00875355 2009-08-26
Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00194766 2007-11-14
Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer
University of Washington
Phase 2 Completed